Risk of Venous Thromboembolism from Use of Dienogest: Experimental Study on Rats | ||||
Egyptian Journal of Histology | ||||
Article 25, Volume 46, Issue 4, December 2023, Page 1893-1899 PDF (488.41 K) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/ejh.2022.154514.1745 | ||||
View on SCiNiTO | ||||
Authors | ||||
Hadeel Anwar Alsarraje 1; Liqaa Khalel Alhyali2 | ||||
1College of Medicine University of Mosul | ||||
2College of Medicine, University of Mosul, Mosul, Iraq | ||||
Abstract | ||||
Background and objective: We aimed to identify the effects of dienogest on inducing thromboembolism in rats following exposure to dienogest for a period of either 10 days (2 estrus cycles), 20 days (4 estrous cycles), or 30 days (6 estrus cycles). Materials and Methods: To do so, 40 rats were divided into 4 groups; dienogest-free control group, dienogest treated for 10 days (G1), 20 days (G2), and 30 days (G3). Then lungs and femoral veins were collected from subjects after sacrificing them, and these tissues were fixed for histological analysis. Results: Results showed that venous thromboembolism increased with dienogest therapy as indicated by the increased score of inflammation in the lung tissues, alongside increased thickness of femoral vein wall, and histological findings of fibrin deposition, vessel congestion, inflammatory cells infiltrations, and epithelial desquamation. Conclusion: To sum up, dienogest long-term therapy could be a risk for cardiac thrombotic diseases, and therefore we do advise using alternative progesterone or adding estrogen in low doses to minimize toxic effects primarily when used as postmenopausal replacement therapy. | ||||
Keywords | ||||
Contraceptives; dienogest; femoral vein; lung; thrombosis | ||||
Statistics Article View: 531 PDF Download: 296 |
||||